AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02626455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide is administered as an infusion at a dose of 750 mg/m2 body surface on Day 2 of each 21-day cycle for patients assigned to R-CHOP
Study NCT02626455 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cyclophosphamide
Description: Cyclophosphamide is administered as an infusion at a dose of 750 mg/m2 body surface on Day 2 of each 21-day cycle for patients assigned to R-CHOP
Study NCT02626455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin is administered as an infusion at a dose of 50 mg/m2 body surface on Day 2 of each 21-day cycle for patients assigned to R-CHOP
Study NCT02626455 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Doxorubicin
Description: Doxorubicin is administered as an infusion at a dose of 50 mg/m2 body surface on Day 2 of each 21-day cycle for patients assigned to R-CHOP
Study NCT02626455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Vincristine is administered as an infusion at a dose of 1.4 mg/m2 body surface (maximum dose 2.0 mg) on Day 2 of each 21-day cycle for patients assigned to R-CHOP
Study NCT02626455 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vincristine
Description: Vincristine is administered as an infusion at a dose of 1.4 mg/m2 body surface (maximum dose 2.0 mg) on Day 2 of each 21-day cycle for patients assigned to R-CHOP
Study NCT02626455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Bendamustine is administered as an infusion at a dose of 90 mg/m2 body surface on Day 1 and Day 2 for patients assigned to R-B
Study NCT02626455 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bendamustine
Description: Bendamustine is administered as an infusion at a dose of 90 mg/m2 body surface on Day 1 and Day 2 for patients assigned to R-B
Study NCT02626455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone is given as 100 mg tablets daily from Day 2 to Day 6 for patients assigned to R-CHOP
Study NCT02626455 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisone
Description: Prednisone is given as 100 mg tablets daily from Day 2 to Day 6 for patients assigned to R-CHOP
Study NCT01803087 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Test treatments CHF 1535 100/6 pMDI (Foster®) TEST1
Study NCT01803087 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CHF 1535 100/6 pMDI (Foster®) using AeroChamber Plus™ (TEST 2).
Study NCT01115179 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Description: Induction with propofol (1.5 to 2mg/kg) and maintenance of anesthesia with propofol 1% (target controlled infusion with concentration levels of 3-5 ug/ml)
Study NCT01115179 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intralipid 10%
Description: Induction of anesthesia with thiopental (3-5mg/kg) and maintenance of anesthesia with isoflurane (end-expired concentration = 0.5%-2.0%) as well as the solvent of propofol 1% (Intralipid 10%; corresponding to a target-controlled infusion of propofol with concentration levels of 3-5ug/ml)
Study NCT01115179 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: Induction of anesthesia with thiopental (3-5mg/kg) and maintenance of anesthesia with isoflurane (end-expired concentration = 0.5%-2.0%)
Study NCT03166995 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low impact aerobic exercise
Description: The intervention will consist of working the muscles that are most affected by FMS through group exercises, which will be dynamic, fluid and aimed at improving functionality. Each session will consist of 60 minutes and will be divided into three parts: warm up (15 minutes); games, group dynamics and aerobics (30 minutes); and cool down with stretching for 15 minutes.
Study NCT01803087 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BDP pMDI 100 µg (Qvar®) plus formoterol fumarate pMDI 6 µg (Atimos®) (REF)
Study NCT01803087 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CHF 1535 100/6 pMDI (Foster®) (CTR)
Study NCT00777868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Strength IDP-108
Description: Topical application once a day for 9 months
Study NCT00777868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Strength IDP-108
Description: Topical application once a day for 9 months
Study NCT00777868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Strength IDP-108 under occlusion
Description: Topical application once a day for 9 months
Study NCT00777868 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Topical application once a day for 9 months
Study NCT03718390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation A
Description: Formulation A (37/40A) of LYN-PLT containing less than 300 mg sucrose within the extended release formulation
Study NCT03718390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation B
Description: Formulation B (46/40A) of LYN-PLT containing less than 300 mg sucrose within the extended release formulation
Study NCT03718390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation C
Description: Formulation C (37/50A) of LYN-PLT containing less than 300 mg sucrose within the extended release formulation
Study NCT03718390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation D
Description: Formulation D (46/50A) of LYN-PLT containing less than 300 mg sucrose within the extended release formulation
Study NCT03718390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation E
Description: Placebo Capsule containing microcrystalline cellulose
Study NCT03718390 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopy
Description: Endoscopy at 2 hours post dosing
Study NCT03718390 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: MRI will be performed on specified days according to protocol
Study NCT04870021 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant hepatitis B vaccine ENGERIX 10 micrograms (µ gm),
Description: recombinant hepatitis B vaccine ENGERIX 10 micrograms (µ gm), intramuscular in the anterolateral part of either of thighs
Study NCT04870021 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Short text messages and calls to parents for compliance to routine immunization schedule
Description: After the discharge of mothers from hospital, preformed, short text messages (SMS) were sent to parents, reminding them of the due date for as per the vaccination schedule. One day after the due date of the vaccine shot, a phone call was made to confirm the child was vaccinated or not
Study NCT04870021 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Short text messages and calls to parents for compliance to routine immunization schedule
Description: After the discharge of mothers from hospital, preformed, short text messages (SMS) were sent to parents, reminding them of the due date for as per the vaccination schedule. One day after the due date of the vaccine shot, a phone call was made to confirm the child was vaccinated or not
Study NCT00189163 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: 30 mg, taken orally, once per day, for 48 weeks
Study NCT00189163 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Sugar Pill, taken orally, once per day, for 48 weeks
Study NCT02990013 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Avenova
Description: Subjects will all undergo the treatment arm where their skin will be cleansed with four different agents: AvenovaTM , povidone-iodine 5% solution, 4% chlorhexidine and isopropyl alcohol
Study NCT02990013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Povidone-iodine 5% solution
Description: Subjects will all undergo the treatment arm where their skin will be cleansed with four different agents: AvenovaTM , povidone-iodine 5% solution, 4% chlorhexidine and isopropyl alcohol
Study NCT02990013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4% chlorhexidine
Description: Subjects will all undergo the treatment arm where their skin will be cleansed with four different agents: AvenovaTM , povidone-iodine 5% solution, 4% chlorhexidine and isopropyl alcohol
Study NCT02990013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isopropyl alcohol
Description: Subjects will all undergo the treatment arm where their skin will be cleansed with four different agents: AvenovaTM , povidone-iodine 5% solution, 4% chlorhexidine and isopropyl alcohol
Study NCT01029262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: One 10 mg Lenalidomide capsule + 2 placebo capsules or (3 placebo capsules) once daily for subjects with a creatinine clearance ≥ 60 mL/min. Alternatively-one 5 mg Lenalidomide capsule + 2 placebo capsules (or 3 placebo capsules) once daily for subjects with a creatinine clearance between 40 and 60 mL/min. Subjects may take study drug for at least 168 days unless there are intolerable side effects or disease progresses. Subjects may continue study drug beyond 168 days if they have an erythroid response (increase in their hemoglobin levels and fewer transfusions administered than before starting study drug)
Study NCT01029262 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 placebo capsules once daily. Subjects may take study drug for at least 168 days unless there are intolerable side effects or disease progresses. Subjects may continue study drug beyond 168 days if they have an erythroid response (increase in their hemoglobin levels and fewer transfusions administered than before starting study drug)
Study NCT03728439 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LED before
Description: Phototherapy will be applied through LED therapy equipment, with 15 light emitting diodes that produce 8 joules (J) per diode and 120 joules in total. The muscular regions irradiated will be the quadriceps, hamstrings and triceps sural, with two points of application in each muscle group.
Study NCT03728439 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LED interval
Description: Phototherapy will be applied through LED therapy equipment, with 15 light emitting diodes that produce 8 joules per diode and 120 joules in total. The muscular regions irradiated will be the quadriceps, hamstrings and triceps sural, with two points of application in each muscle group.
Study NCT03728439 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LED after
Description: Phototherapy will be applied through LED therapy equipment, with 15 light emitting diodes that produce 8 joules per diode and 120 joules in total. The muscular regions irradiated will be the quadriceps, hamstrings and triceps sural, with two points of application in each muscle group.
Study NCT00553488 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regular insulin (Humulin)
Description: Insulin will be given either subcutaneously or intra-dermally, and at two different times prior to the liquid meal (T zero). At -17 mins, regular insulin will be given either SC or ID. At -2 mins, regular insulin will be given ID; also insulin lispro will be given either SC or ID. Each patient will receive 1 injection on 5 different study days.
Study NCT00553488 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin lispro (Humalog)
Description: Insulin will be given either subcutaneously or intra-dermally, and at two different times prior to the liquid meal (T zero). At -17 mins, regular insulin will be given either SC or ID. At -2 mins, regular insulin will be given ID; also insulin lispro will be given either SC or ID. Each patient will receive 1 injection on 5 different study days.
Study NCT03166995 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Postural exercises
Description: The intervention will consist of performing postural exercises in prone, supine, sitting and standing position, as well as in quadrupedia. Each session will consist of 60 minutes and will be divided into three parts: warm up (15 minutes); postural exercises (30 minutes); and cool down with stretching for 15 minutes.
Study NCT03381677 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pedicle Lengthening Osteotomy with Altum® Device
Description: Decompressive surgery via Pedicle lengthening osteotomy using Altum Device. Altum is intended for pedicle lengthening to correct degenerative lumbar spinal stenosis in the presence of a grade 1 degenerative spondylolisthesis. The Altum bone saw is designed for creating an osteotomy at the base of each pedicle. The Altum implant is designed for distraction of the pedicle osteotomy and for lengthening of the pedicles. Altum is appropriate for skeletally mature adults with symptomatic stenosis at one or two levels between L2-L5.
Study NCT03381677 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Decompressive surgery via open surgical decompression and Transforaminal Lumbar Interbody Fusion (TLIF) using either a midline or paramedian incision with implantation of bilateral pedicle screws (4 screws) and rods (2 rods) and an interbody fusion cage (1 PEEK fusion cage, coated or uncoated):~1. DePuy Synthes Expedium® 5.5 System, Stryker Xia 5.5 System, Medtronic CD Horizon Solera 5.5 Systemor Innovative Surgical Designs True Spinal Fixation System; and~2. DePuy Synthes Concord TLIF cage, Stryker UniLIF TLIF cage, Medtronic Capstone TLIF cage or Meditech Talos TLIF cage.
Study NCT02821351 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radio frequency (RF) Cardiac ablation
Description: Catheter based RF cardiac ablation to treat Paroxysmal Atrial Fibrillation
Study NCT03628547 — intervention group
Intervention type: BEHAVIORAL
Intervention: Measuring devices and questionnaires
Description: Measuring devices and questionnaires will be applied to assess the pain and psychosocial states of musculoskeletal system of athletes. The Expanded Scandinavian Muscle Skeleton Questionnaire (NMQ) and Visible Analogue Scale (VAS) will be used to identify and assess the symptoms of musculoskeletal discomfort as 'pain'. The participant will be evaluated with the algometer, the sporty trust will be questioned with the Sporty Trust Continuous Inventory, and the Quality of Life will be assessed with the World Health Organization Quality of Life Scale Short Form and Depression will be evaluated with Beck Depression Inventory.
Study NCT01622062 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PVRV
Description: 0.1 mL, 4 site 'one week' (4-4-4-0-0) administered intradermally
Study NCT01622062 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PVRV and pERIG Favirab®
Description: 0.1 mL of vaccine administered intradermally in 4 site 'one week' (4-4-4-0-0) regimen, and pERIG Favirab® (volume to be calculated according to the patient' body weight) infiltrated into and around wound(s)
Study NCT01622062 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PVRV and pERIG Favirab®
Description: 0.1 mL of vaccine administered intradermally in 2-site TRC (2-2-2-0-2) regimen, and pERIG Favirab® (volume to be calculated according to the patient' body weight) infiltrated into and around wound(s)
Study NCT05164380 — intervention group
Intervention type: OTHER
Intervention: Picture naming tasks
Description: PWA and CG had to name 128 pictures presented on a tablet, in addition to 8 trial images.
Study NCT00002745 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aminocamptothecin
Description: 850 micrograms/square meter/day (total dose 2550 micrograms/square meter) via central venous catheter using infusion pump over 72 hours + one cycle Cycle repeated every 14 days for minimum of 6 cycles if partial or complete response
Study NCT03776708 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spinal manipulation
Description: Spinal manipulation is defined as a quick, passive and forced manoeuvre applied to spinal joints, and sometimes followed by a characteristic cracking sound. It can be compared to a mobilisation, which is a passive manual therapy as well, but is applied slower and repetitively on the joints. Spinal manipulation has been shown to have a significant clinical impact in the treatment of musculoskeletal pain
Study NCT03776708 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham procedure
Description: The sham procedure is a manual contact on both inferior angles of the scapulae by the chiropractor. After a short tensioning, a slight movement with low velocity and low amplitude is done, respecting scapula-thoracic sliding plans laterally, without repercussion on the spine. It is considered by us to be a credible sham procedure, as it resembles an actual act of thoracic manipulation, and it has been validated, with questionnaires
Study NCT06045052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Description: Eltrombopag tablets by mouth once daily for 24 weeks (6 months) with the dose depending on race, age and weight.
Study NCT02630680 — intervention group
Intervention type: DRUG
Intervention: Eziclen®/Izinova®
Study NCT00263367 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Hyperbaric Oxygen
Description: Hyperbaric Oxygen at 1.3 ATA for one hour
Study NCT04080037 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality IQ Patient Simulations
Description: Online patient cases designed to simulate typical patients seen in a primary care practice. In each case, providers will answer multiple-choice questions about their preferred course of action to work-up, diagnose and treat patients in the primary care setting. After each question, providers will receive evidence-based feedback, including references, on the appropriateness of each of their care decisions. Feedback will be supported with relevant reference to evidence-based guidelines, with a specific focus on the CDC opioid guidelines.~Cases will cover typical primary care patients presenting with acute and chronic pain, who may or may not be already taking opioid medication.
Study NCT00925678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DSP-3025
Study NCT00925678 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03771794 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ReguRate neurostimulation
Description: Device: ReguRate neurostimulation Device:~Sham : ReguRate neurostimulation - mock sham stimulation mode
Study NCT03771794 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: ReguRate neurostimulation
Description: Device: ReguRate neurostimulation Device:~Sham : ReguRate neurostimulation - mock sham stimulation mode
Study NCT06170177 — intervention group
Intervention type: PROCEDURE
Intervention: Radical Cystectomy
Description: A radical cystectomy is an operation to remove the whole bladder
Study NCT03942692 — intervention group
Intervention type: OTHER
Intervention: Phone call questionnaire
Description: Questionnaire for parents of subject about :~* the frequency of consultations with an allergist~* the information of the general practitioner or pediatrician~* the prescription of epinephrin auto-injector~* the frequency of renewal of epinephrin auto-injector~* the specialty of doctor who prescribed the renewal~* the implementation of specific measures in schools~* the frequency of renewal of specific measures in schools~* the number of recurrence of anaphylactic reaction~* the use of medical advice in case of recurrence of anaphylactic reaction
Study NCT00071461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bosentan
Description: Initial dose: 62.5 mg b.i.d. for 4 weeks.~* Target dose: - body weight > 40 kg (90 lb): 125 mg b.i.d., (if the initial dose is well tolerated).~* body weight \< 40 kg (90 lb): 62.5 mg b.i.d.
Study NCT00071461 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Initial dose: 62.5 mg b.i.d. for 4 weeks.~* Target dose: - body weight > 40 kg (90 lb): 125 mg b.i.d., (if the initial dose is well tolerated).~* body weight \< 40 kg (90 lb): 62.5 mg b.i.d.
Study NCT03556787 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BPI 1000013 (Dr Scholls Insole)
Description: Full length foam insole
Study NCT04288505 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: VIRTUAL REALITY application
Description: application on virtual reality headset
Study NCT01865747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib tablets
Study NCT01865747 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus (Afinitor) tablets
Study NCT01133418 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computerized Progressive Attention Training
Description: Four comprehensive training tasks were developed and programmed based on expansions and modifications of various tasks that have been extensively investigated in the attention literature and are known to reflect primary attentional functions. Each task is discussed in detail in the Research Methods (section D.6.b). Briefly, they included a Continuous Performance Task, a Conjunctive Search Task, an Orienting and Flanker Task, and a Global-Local Task. All of the tasks were modified extensively from their original neuropsychological design to make them entertaining and stimulating enough for children to enjoy. Each task began at a relatively simple level of difficulty and gradually increased in difficulty across the training as children demonstrated proficiency according to reductions in RT variability
Study NCT01133418 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Comparator Cognitive Training
Description: Same tasks at Computerized Progressive Attention Training but the tasks do not progress in difficulty
Study NCT00022581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thalidomide
Description: Given orally